[go: up one dir, main page]

PE20220142A1 - Anticuerpos de cadena pesada que se unen al psma - Google Patents

Anticuerpos de cadena pesada que se unen al psma

Info

Publication number
PE20220142A1
PE20220142A1 PE2021001667A PE2021001667A PE20220142A1 PE 20220142 A1 PE20220142 A1 PE 20220142A1 PE 2021001667 A PE2021001667 A PE 2021001667A PE 2021001667 A PE2021001667 A PE 2021001667A PE 20220142 A1 PE20220142 A1 PE 20220142A1
Authority
PE
Peru
Prior art keywords
heavy chain
psma
seq
nos
bind
Prior art date
Application number
PE2021001667A
Other languages
English (en)
Inventor
Schooten Wim Van
Starlynn Clarke
Kevin Dang
Ben Buelow
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of PE20220142A1 publication Critical patent/PE20220142A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere a anticuerpos de cadena pesada que se unen a PSMA (Antigeno prostatico especifico de membrana), donde una primera o segunda region variable de cadena pesada comprende: una CDR1 seleccionada de las SEQ ID NO: 1-10; una CDR2 seleccionada de las SEQ ID NO: 11-17 y; una CDR3 seleccionada de las SEQ ID NO: 18-23. Adicionalmente, el anticuerpo comprende una secuencia de region variable de cadena pesada seleccionada de las SEQ ID NO: 24 a 58. La invencion tambien se refiere a un polinucleotido, un vector, una celula, una composicion farmaceutica, metodos de uso y produccion que comprenden dichos anticuerpos. Los anticuerpos anti-PSMA presentados en la invencion son utiles en trastornos asociados a la expresion de la proteina PSMA tal como el cancer de prostata.
PE2021001667A 2019-04-05 2020-04-03 Anticuerpos de cadena pesada que se unen al psma PE20220142A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962830130P 2019-04-05 2019-04-05
PCT/US2020/026686 WO2020206330A1 (en) 2019-04-05 2020-04-03 Heavy chain antibodies binding to psma

Publications (1)

Publication Number Publication Date
PE20220142A1 true PE20220142A1 (es) 2022-01-27

Family

ID=70476405

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001667A PE20220142A1 (es) 2019-04-05 2020-04-03 Anticuerpos de cadena pesada que se unen al psma

Country Status (18)

Country Link
US (3) US12180298B2 (es)
EP (1) EP3947470A1 (es)
JP (1) JP7776987B2 (es)
KR (1) KR20210149076A (es)
CN (1) CN113710707B (es)
BR (1) BR112021019334A2 (es)
CA (1) CA3133654A1 (es)
CL (1) CL2021002586A1 (es)
CO (1) CO2021013279A2 (es)
CR (1) CR20210500A (es)
EA (1) EA202192736A1 (es)
IL (1) IL286398A (es)
JO (1) JOP20210253A1 (es)
MX (1) MX2021012205A (es)
PE (1) PE20220142A1 (es)
PH (1) PH12021552538A1 (es)
SG (1) SG11202111027WA (es)
WO (1) WO2020206330A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7432363B2 (ja) 2016-06-21 2024-02-16 テネオバイオ， インコーポレイテッド Ｃｄ３結合抗体
AU2017316604C1 (en) 2016-08-24 2025-01-30 Teneobio, Inc. Transgenic non-human animals producing modified heavy chain-only antibodies
CR20220408A (es) 2016-09-14 2022-10-20 Teneobio Inc ANTICUERPOS DE UNIÓN A CD3(Divisional del Expediente 2019-198)
BR112019012354A2 (pt) 2016-12-21 2019-11-26 Teneobio Inc anticorpos apenas de cadeia pesada anti-bcma
JP7240335B2 (ja) 2017-06-20 2023-03-15 テネオワン， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
IL271194B2 (en) 2017-06-20 2024-10-01 Teneobio Inc Anti-bcma heavy chain-only antibodies
CN111683966B (zh) 2017-12-22 2023-07-11 特尼奥生物股份有限公司 与cd22结合的重链抗体
EA202192736A1 (ru) 2019-04-05 2022-01-27 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с псма
BR112021024956A2 (pt) 2019-06-14 2022-01-25 Teneobio Inc Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
US20230203161A1 (en) 2020-04-29 2023-06-29 Teneobio, Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
TW202406932A (zh) * 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
TW202233684A (zh) * 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
EP4284838A2 (en) * 2021-01-28 2023-12-06 Janssen Biotech, Inc. Psma binding proteins and uses thereof
WO2022183074A2 (en) * 2021-02-25 2022-09-01 Teneobio, Inc. Anti-psma antibodies and car-t structures
EP4323403A1 (en) * 2021-04-16 2024-02-21 Teneobio, Inc. Anti-cd20 antibodies and car-t structures
WO2022232376A1 (en) 2021-04-29 2022-11-03 Amgen Inc. Methods for reducing low molecular weight species of recombinantly-produced proteins
JP2025509892A (ja) 2022-03-21 2025-04-11 アムジェン インコーポレイテッド 前立腺癌の治療のためのｔ細胞エンゲージ分子を用いた併用療法
CN119552258B (zh) * 2023-09-01 2025-11-07 北京智仁美博生物科技有限公司 结合hla-a02/mage-a4复合体的多种抗体及其用途

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5968509A (en) 1990-10-05 1999-10-19 Btp International Limited Antibodies with binding affinity for the CD3 antigen
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9206422D0 (en) 1992-03-24 1992-05-06 Bolt Sarah L Antibody preparation
US7381803B1 (en) 1992-03-27 2008-06-03 Pdl Biopharma, Inc. Humanized antibodies against CD3
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP0904107B1 (en) 1996-03-18 2004-10-20 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
ES2246069T3 (es) 1997-05-02 2006-02-01 Genentech, Inc. Procedimiento de preparacion de anticuerpos multiespecificos que tienen componentes comunes y multimericos.
CN101518648A (zh) 1999-01-07 2009-09-02 津莫吉尼蒂克斯公司 可溶性受体br43×2和应用方法
KR20090016772A (ko) 1999-08-17 2009-02-17 바이오겐 아이덱 엠에이 인코포레이티드 Ｂａｆｆ 수용체(ｂｃｍａ), 면역조절제
AU6232899A (en) 1999-10-06 2001-05-10 Campina Melkunie B.V. Use of transforming growth factor beta and growth factors in the treatment and prevention of diseases of the intestinal mucosa
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
MXPA02010011A (es) 2000-04-11 2003-04-25 Genentech Inc Anticuerpos multivalentes y usos para los mismos.
ES2287130T3 (es) 2000-05-12 2007-12-16 Amgen Inc. Polipeptidos para inhibir la proliferacion de celulas b y t inducida por april.
AU2002238052A1 (en) 2001-02-20 2002-09-04 Zymogenetics, Inc. Antibodies that bind both bcma and taci
CN1195779C (zh) 2001-05-24 2005-04-06 中国科学院遗传与发育生物学研究所 抗人卵巢癌抗人cd3双特异性抗体
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
MXPA05004677A (es) 2002-10-31 2005-11-17 Genentech Inc Metodos y composiciones para aumentar la produccion de anticuerpos.
US7575893B2 (en) 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
RU2005137325A (ru) 2003-05-31 2006-09-10 Микромет Аг (De) Фармацевтическая композиция, содержащая конструкт, специфичный к ерсам
CA2522586C (en) 2003-05-31 2017-02-21 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
JP4948174B2 (ja) 2003-10-16 2012-06-06 マイクロメット アクツィエン ゲゼルシャフト 多重特異的脱免疫ｃｄ３−結合物質
MXPA06005941A (es) 2003-12-10 2006-08-23 Medarex Inc Anticuerpos ip-10 y sus usos.
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
US7728114B2 (en) 2004-06-03 2010-06-01 Novimmune S.A. Anti-CD3 antibodies and methods of use thereof
EP2311874B1 (en) 2004-07-22 2017-05-31 Erasmus University Medical Center Rotterdam Binding molecules
AU2006214033B2 (en) 2005-02-18 2011-08-11 Medarex, L.L.C. Monoclonal antibodies against CD30 lacking fucosyl residues
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc SELF-BUFFING PROTEIN FORMULATIONS
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
AU2006291005A1 (en) 2005-09-12 2007-03-22 Novimmune S.A. Anti-CD3 antibody formulations
AU2006301492B2 (en) 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
WO2007062090A2 (en) 2005-11-23 2007-05-31 Genentech, Inc. Methods and compositions related to b cell assays
AU2006323415A1 (en) 2005-12-06 2007-06-14 Domantis Limited Bispecific ligands with binding specificity to cell surface targets and methods of use therefor
WO2007117600A2 (en) 2006-04-07 2007-10-18 Macrogenics, Inc. Combination therapy for treating autoimmune diseases
US7862813B2 (en) 2006-07-29 2011-01-04 Bjork Jr Robert Lamar Bi-specific monoclonal antibody (specific for both CD3 and CD11b) therapeutic drug
PT2520590T (pt) 2007-04-03 2018-11-14 Amgen Res Munich Gmbh Domínio de ligação específico de espécies cruzadas
HRP20120759T1 (hr) 2007-04-03 2012-10-31 Amgen Research (Munich) Gmbh Bispecifična veziva specifična između vrsta
ES2432792T5 (es) 2007-04-03 2023-01-16 Amgen Res Munich Gmbh Dominio de unión a CD3-épsilon específico de especies cruzadas
DK2152880T3 (da) 2007-06-01 2011-11-28 Omt Inc Sammensætninger og fremgangsmåder til hæmning af endogene immunoglobulingener og produktion af transgene, humane idiotype antistoffer
WO2009132058A2 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
KR20110059755A (ko) 2008-09-19 2011-06-03 메디뮨 엘엘씨 소닉 헤지혹 호모로그에 대한 항체 및 이의 용도
AU2009299793B2 (en) 2008-10-01 2016-03-10 Amgen Research (Munich) Gmbh Bispecific single chain antibodies with specificity for high molecular weight target antigens
KR101820535B1 (ko) 2008-10-01 2018-01-19 암젠 리서치 (뮌헨) 게엠베하 종간특이적 ｐｓｍａｘｃｄ3 이중특이적 단일쇄 항체
US10981998B2 (en) 2008-10-01 2021-04-20 Amgen Research (Munich) Gmbh Cross-species-specific single domain bispecific single chain antibody
RU2547600C2 (ru) 2008-10-01 2015-04-10 Эмджен Рисерч (Мьюник) Гмбх Pscaxcd3, cd19xcd3, c-metxcd3, эндосиалинxcd3, epcamxcd3, igf-1rxcd3 или fap-альфаxcd3 биспецифическое одноцепочечное антитело с межвидовой специфичностью
DK2406284T5 (en) 2009-03-10 2017-06-12 Biogen Ma Inc ANTI-BCMA ANTIBODIES
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
JP5955781B2 (ja) 2010-02-08 2016-07-20 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 共通の軽鎖のマウス
TWI653333B (zh) 2010-04-01 2019-03-11 安進研究（慕尼黑）有限責任公司 跨物種專一性之ＰＳＭＡｘＣＤ３雙專一性單鏈抗體
US20130273055A1 (en) 2010-11-16 2013-10-17 Eric Borges Agents and methods for treating diseases that correlate with bcma expression
WO2012122512A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Recombinant production of mixtures of single chain antibodies
CA2828347A1 (en) 2011-03-10 2012-09-13 Hco Antibody, Inc. Bispecific three-chain antibody-like molecules
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
CA2833019A1 (en) 2011-04-22 2012-10-26 Emergent Product Development Seattle, Llc Prostate-specific membrane antigen binding proteins and related compositions and methods
AU2012264890C1 (en) 2011-05-27 2016-03-10 Glaxo Group Limited BCMA (CD269/TNFRSF17) -binding proteins
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
UA119227C2 (uk) 2012-04-20 2019-05-27 Аптево Рісьорч Енд Девелопмент Ллс Поліпептид, що зв'язується з cd3
BR112014032916A2 (pt) 2012-06-28 2017-08-01 Pfizer anticorpos anti-fármacos e usos destes para o monitoramento de fármaco
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
AU2013340799B2 (en) 2012-11-01 2018-08-09 Max-Delbruck-Centrum Fur Molekulare Medizin (Mdc) An antibody that binds CD269 (BCMA) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
PL2931030T5 (pl) 2012-12-14 2024-06-10 Open Monoclonal Technology, Inc. Polinukleotydy kodujące przeciwciała gryzoni z ludzkimi idiotypami i zawierające je zwierzęta
EP2762496A1 (en) 2013-02-05 2014-08-06 EngMab AG Method for the selection of antibodies against BCMA
DK2953972T3 (da) 2013-02-05 2020-10-12 Engmab Sarl Fremgangsmåde til udvælgelse af antistoffer mod bcma
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
AU2014261630B2 (en) 2013-04-29 2019-05-09 F. Hoffmann-La Roche Ag Human FcRn-binding modified antibodies and methods of use
CA2927099A1 (en) 2013-10-31 2015-05-07 Sanofi Specific anti-cd38 antibodies for treating human cancers
CN105873953A (zh) 2013-11-04 2016-08-17 格兰马克药品股份有限公司 重靶向t细胞的异源二聚免疫球蛋白的产生
WO2015095412A1 (en) 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
WO2015121383A1 (en) 2014-02-12 2015-08-20 Michael Uhlin Bispecific antibodies for use in stem cell transplantation
CA2935748A1 (en) 2014-02-25 2015-09-03 Immunomedics, Inc. Humanized rfb4 anti-cd22 antibody
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
RS59907B1 (sr) 2014-03-28 2020-03-31 Xencor Inc Bispecifična antitela koja se vezuju za cd38 i cd3
JP7054622B2 (ja) 2014-07-21 2022-04-14 ノバルティス アーゲー ヒト化抗ｂｃｍａキメラ抗原受容体を使用した癌の処置
WO2016014974A2 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
SG11201702502XA (en) 2014-10-22 2017-05-30 Crescendo Biolog Ltd Transgenic mice
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
HUE049650T2 (hu) 2014-11-20 2020-11-30 Hoffmann La Roche Közös könnyûláncok és alkalmazási eljárások
HK1245801B (en) 2014-12-12 2020-05-15 2Seventy Bio, Inc. Bcma chimeric antigen receptors
GB201500461D0 (en) 2015-01-12 2015-02-25 Cresendo Biolog Ltd Therapeutic molecules
WO2016187546A1 (en) 2015-05-20 2016-11-24 Janssen Biotech, Inc. Anti-cd38 antibodies for treatment of light chain amyloidosis and other cd38-positive hematological malignancies
IL274151B (en) 2015-05-21 2022-07-01 Harpoon Therapeutics Inc Trispecific binding proteins and methods of use
JOP20160154B1 (ar) 2015-07-31 2021-08-17 Regeneron Pharma أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
JO3799B1 (ar) 2015-08-17 2021-01-31 Janssen Pharmaceutica Nv الأجسام المضادة ل bcma، جزيئات ربط الانتيجين ثنائية التحديد التي تربط bcma و cd3، و استخداماتها
US10865249B2 (en) 2015-11-10 2020-12-15 University Medical Center Hamburg-Eppendorf Antigen-binding polypeptides directed against CD38
JP7190901B2 (ja) * 2016-01-12 2022-12-16 クレッシェンド、バイオロジックス、リミテッド 前立腺特異的膜抗原（ｐｓｍａ）と結合する分子
KR20240118898A (ko) 2016-02-03 2024-08-05 암젠 리서치 (뮌헨) 게엠베하 Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
CN105968203A (zh) * 2016-02-03 2016-09-28 南昌大学 一种抗前列腺特异性膜抗原胞外区的单域重链抗体
CN105968204B (zh) 2016-02-03 2020-01-21 中国人民解放军第三军医大学第一附属医院 一种抗前列腺特异性膜抗原的单域重链抗体
JP7432363B2 (ja) 2016-06-21 2024-02-16 テネオバイオ， インコーポレイテッド Ｃｄ３結合抗体
AU2017316604C1 (en) 2016-08-24 2025-01-30 Teneobio, Inc. Transgenic non-human animals producing modified heavy chain-only antibodies
CR20220408A (es) 2016-09-14 2022-10-20 Teneobio Inc ANTICUERPOS DE UNIÓN A CD3(Divisional del Expediente 2019-198)
MX2019006043A (es) 2016-11-23 2019-09-26 Harpoon Therapeutics Inc Proteína de unión de antígeno prostático específico de membrana.
BR112019012354A2 (pt) 2016-12-21 2019-11-26 Teneobio Inc anticorpos apenas de cadeia pesada anti-bcma
JP7240335B2 (ja) 2017-06-20 2023-03-15 テネオワン， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
IL271194B2 (en) 2017-06-20 2024-10-01 Teneobio Inc Anti-bcma heavy chain-only antibodies
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
SG11201913175TA (en) 2017-06-30 2020-01-30 The United States Of America As Represented By The Secretary Anti-b-cell maturation antigen chimeric antigen receptors with human domains
GB201711068D0 (en) * 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
EP3681908A1 (en) 2017-09-13 2020-07-22 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
KR20200061402A (ko) 2017-10-10 2020-06-02 사노피 항-cd38 항체 및 항-cd3 및 항-cd28 항체와의 조합
US20200262920A1 (en) 2017-10-12 2020-08-20 Amphivena Therapeutics Inc. Dosing regimen for cd3 binding proteins
CN111683966B (zh) 2017-12-22 2023-07-11 特尼奥生物股份有限公司 与cd22结合的重链抗体
JP2021508479A (ja) 2017-12-27 2021-03-11 テネオバイオ， インコーポレイテッド ヘテロ二量体特異的抗体上のｃｄ３デルタ及びｃｄ３イプシロン
AU2019275284A1 (en) 2018-05-24 2021-01-14 Ayala Pharmaceuticals Inc. Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof
JP7439046B2 (ja) 2018-07-20 2024-02-27 テネオツー・インコーポレイテッド Ｃｄ１９に結合する重鎖抗体
EP3853253A2 (en) 2018-09-21 2021-07-28 TeneoBio, Inc. Methods for purifying heterodimeric, multispecific antibodies
JP2022505445A (ja) 2018-10-26 2022-01-14 テネオバイオ， インコーポレイテッド Ｃｄ３８に結合する重鎖抗体
EA202192736A1 (ru) 2019-04-05 2022-01-27 Тенеобио, Инк. Антитела, содержащие только тяжелые цепи, которые связываются с псма
BR112021024956A2 (pt) 2019-06-14 2022-01-25 Teneobio Inc Anticorpos multiespecíficos de cadeia pesada que se ligam a cd22 e cd3
EP4077391A1 (en) 2019-12-18 2022-10-26 Teneofour, Inc. Heavy chain antibodies binding to cd38
CN115803057A (zh) 2020-04-29 2023-03-14 特纳奥尼公司 治疗多发性骨髓瘤的方法
US20230203161A1 (en) * 2020-04-29 2023-06-29 Teneobio, Inc Multispecific heavy chain antibodies with modified heavy chain constant regions
CA3214992A1 (en) 2020-04-29 2021-11-04 Teneobio, Inc. Multispecific heavy chain antibodies with modified heavy chain constant regions
TWI894270B (zh) 2020-05-11 2025-08-21 美商健生生物科技公司 用於治療多發性骨髓瘤之方法
AU2021300179A1 (en) 2020-06-30 2023-02-02 Teneobio, Inc. Multi-specific antibodies binding to BCMA
TW202233684A (zh) 2020-11-18 2022-09-01 美商泰尼歐生物公司 結合於葉酸受體α之重鏈抗體
WO2022183074A2 (en) 2021-02-25 2022-09-01 Teneobio, Inc. Anti-psma antibodies and car-t structures
CN116917327A (zh) 2021-02-26 2023-10-20 特尼奥生物股份有限公司 抗muc1-c抗体及car-t结构
TW202304994A (zh) 2021-04-02 2023-02-01 美商泰尼歐生物公司 促效性抗ｉｌ－２ｒ抗體及使用方法
JP2024514107A (ja) 2021-04-06 2024-03-28 テネオバイオ， インコーポレイテッド 抗ｃｄ１９抗体及びｃａｒ－ｔ構造体
EP4323403A1 (en) 2021-04-16 2024-02-21 Teneobio, Inc. Anti-cd20 antibodies and car-t structures
WO2022271987A1 (en) 2021-06-23 2022-12-29 TeneoFour, Inc. Anti-cd38 antibodies and epitopes of same
WO2023004197A1 (en) 2021-07-23 2023-01-26 Teneoten, Inc. Heavy chain antibodies binding to hepatitis b surface antigen
US20240400716A1 (en) * 2021-11-09 2024-12-05 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Molecules that bind to prostate specific membrane antigen (psma) polypeptides
JP2025508827A (ja) * 2022-02-23 2025-04-10 ゼンコア インコーポレイテッド 抗ｃｄ２８×抗ｐｓｍａ抗体
WO2023193015A1 (en) * 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies

Also Published As

Publication number Publication date
IL286398A (en) 2021-10-31
US12180298B2 (en) 2024-12-31
US20220195068A1 (en) 2022-06-23
CR20210500A (es) 2021-11-05
EP3947470A1 (en) 2022-02-09
JOP20210253A1 (ar) 2023-01-30
CN113710707B (zh) 2024-05-31
CO2021013279A2 (es) 2022-01-17
JP7776987B2 (ja) 2025-11-27
WO2020206330A1 (en) 2020-10-08
PH12021552538A1 (en) 2022-07-04
BR112021019334A2 (pt) 2021-12-07
KR20210149076A (ko) 2021-12-08
MX2021012205A (es) 2022-02-21
EA202192736A1 (ru) 2022-01-27
CL2021002586A1 (es) 2022-05-06
CA3133654A1 (en) 2020-10-08
JP2022526595A (ja) 2022-05-25
US20250236681A1 (en) 2025-07-24
CN113710707A (zh) 2021-11-26
SG11202111027WA (en) 2021-11-29
US20230242668A1 (en) 2023-08-03
AU2020252556A1 (en) 2021-10-21

Similar Documents

Publication Publication Date Title
PE20220142A1 (es) Anticuerpos de cadena pesada que se unen al psma
PE20190976A1 (es) Anticuerpos de union a cd3
SA522440090B1 (ar) معقدات بولي ببتيد ثنائية الخصوصية جديدة
PE20180046A1 (es) Anticuerpos terapeuticos y sus usos
PE20211284A1 (es) Anticuerpos anti-nkg2a y usos de los mismos
AR102698A1 (es) Anticuerpos contra cd73 y sus usos
PE20141908A1 (es) Anticuerpos cd47 y metodos de uso los mismos
PE20190975A1 (es) Novela cd47 anticuerpos monoclonales y sus usos
EA202092410A1 (ru) Конъюгаты камптотецина с пептидом
CL2019001926A1 (es) Anticuerpos anti-tigit y fragmentos de unión a antígeno; composición farmacéutica que los comprende; polinenucleótido que codifica dicho anticuerpo; vector que los comprende, célula hospedera; método para producir dicho anticuerpo o fragmento de unión a antígeno del mismo; y uso en el tratamiento del cáncer. (divisional de solicitud 310-2017).
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
CO2019003923A2 (es) Anticuerpos anti-steap2, conjugados anticuerpo-fármaco, y moléculas de fijación al antígeno biespecíficas que se fijan a steap2 y cd3, y usos de estos
AR106184A1 (es) Proteínas de unión a pd-1 y sus métodos de uso
PE20190737A1 (es) Anticuerpos anti-cd27
AR106570A1 (es) Anticuerpos anti-psma, moléculas de unión al antígeno biespecíficas que se unen a psma y cd3, y usos de estos
PE20201255A1 (es) Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos
CO6251370A2 (es) Una molecula de union cd20 humanizda que comprende un dominio variable de cadena pesada de inmunoglobulina (vh) y un dominio variable de cadena liviana de inmunoglobulina (vl) y metodos de uso de la misma
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
PE20171180A1 (es) Anticuerpos anti-pd-1 y sus metodos de uso
PE20180249A1 (es) Anticuerpos neutralizadores anti-ccl20
PE20210517A1 (es) Anticuerpos anti-hla-g y utilizacion de los mismos
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
PE20201149A1 (es) Anticuerpos de union a hla-a2/wt1
PE20200927A1 (es) Anticuerpos monoclonales que se unen a la region de la cadena beta de la familia trbv9 del receptor de las celulas t humanas
AR109683A1 (es) Anticuerpos contra el factor xi y sus usos